AI sits at a crossroads in biopharma. While Google’s Gemma model successfully identified a cancer pathway, the industry faces a reality check. Meanwhile, Translational genomics is drowning in data without clear navigation, and Gartner places Gen AI in the "Trough of Disillusionment" due to unmet promises.

Zifo’s Data Readiness Survey confirms this tension: companies are investing heavily, but most work remains foundational -- cleaning data and aligning standards. Real value lies in balancing flashy breakthroughs with the essential, behind-the-scenes work that drives science.